Please login to the form below

Not currently logged in

BMS' Opdivo set for early access in UK

First anti-PD1 to be given fast-track status in the country

Bristol-Myers Squibb (BMS) buildingBristol-Myers Squibb (BMS) could see an early launch of its new melanoma therapy Opdivo in the UK after becoming the first drug of its class given a new fast-track status by the country's drugs regulator.

The Medicines and Healthcare products Regulatory Agency (MHRA) has labelled PD-1 inhibitor Opdivo (nivolumab) a Promising Innovative Medicine (PIM), the first stage in the UK's Early Access to Medicines Scheme (EAMS) which was launched in April 2014.

PIM is an early signal to companies that their development plans for a new therapy are on the right track for the EASM, which aims to increase patient access to medicines where there is an unmet medical need.

Until now, the only PIM granted under the scheme was for Northwest Biotherapeutics' cell-based therapy DCVax-L for a form of brain cancer known as malignant glioma.

The award of PIM status is followed by a review of the benefit and risks of the medicine by the MHRA, which then delivers a scientific opinion based on the data available at the time of the EAMS submission. In that respect it is similar to the 'breakthrough' designation recently introduced by the US FDA.

According to the regulator, the opinion "will support the prescriber and patient to make a decision on whether to use the medicine before its licence is approved."

The PIM award for Opdivo comes on the back of robust efficacy data for the immuno-oncology therapy in melanoma, an indication for which it has already been approved in Japan and the US.

When the EASM was launched it was feted by Health Secretary Jeremy Hunt as a major boost for the UK life sciences industry, although companies were a little more guarded in their response.

Whilst backing the approach in principle, the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) had qualms about the funding of the scheme, in particular that companies will foot the bill for making the drugs available under the EASM.  

Drugs made available under the new process will be effectively free for NHS patients, but it has been suggested that some companies - and particularly smaller enterprises making drugs that are expensive to manufacture - will be unable to afford to take part.

"We are … delighted that nivolumab has become one of the first medicines to be awarded a PIM designation,” commented Johanna Mercier, general manager of BMS UK & Ireland.

"We will now work closely with the NHS to ensure all those eligible are able to benefit from this breakthrough treatment as soon as possible," she promised.

Article by
Phil Taylor

8th January 2015

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...